首页> 外文期刊>Molecular and Cellular Biochemistry >PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells
【24h】

PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells

机译:PTEN状态与神经胶质瘤起始细胞中的细胞增殖和自我更新无关,而与CD133表型无关

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

CD133 is extensively used as a surface marker to identify and isolate glioma-initiating cells (GICs) from malignant brain tumors; however, instances of CD133− cells exhibiting similar properties have also been reported. To clarify the availability of CD133 as the GIC marker, we first evaluated the ratio of CD133+ cells and malignancy of glioma spheroids GIC1 and GIC2, respectively. GIC1, which showed a lower percentage of CD133+ cells, exhibited a highly aggressive behavior in comparison with GIC2. The following experiments demonstrated that tumor suppressor PTEN was lost in GIC1, resulting in the activation of AKT pathway. Overexpression of recombinant PTEN in GIC1 suppressed its proliferation and self-renew without significant effect on CD133 expression level, indicating that the inconsistence between the ratio of CD133+ cells and proliferation and self-renewal capacity of GIC1 and GIC2 was caused by PTEN deficiency. To further validate our conclusion, a series of GICs were analyzed and the percentages of CD133+ cells could not reflect the degrees of cell proliferation and self-renewal characteristics in the PTEN deficient GICs, suggesting that the application of CD133 as the GIC maker was restricted by PTEN loss. Furthermore, down-regulation of PTEN in the PTEN-expressing GICs could break the positive correlation between the ratio of CD133+ cells and proliferation and self-renewal capacity. Our results demonstrated that PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells, resulting in the limitations of CD133 as a biomarker for PTEN deficient GICs.
机译:CD133被广泛用作表面标志物,以从恶性脑肿瘤中鉴定和分离神经胶质瘤起始细胞(GIC)。然而,也已经报道了表现出相似性质的CD133 -细胞的实例。为了阐明CD133作为GIC标记的可用性,我们首先评估了CD133 + 细胞的比例和神经胶质瘤球体GIC1和GIC2的恶性程度。与GIC2相比,GIC1的CD133 + 细胞百分比较低,表现出高度的侵略性。以下实验表明,抑癌基因PTEN在GIC1中丢失,从而导致AKT通路的激活。重组PTEN在GIC1中的过表达抑制了其增殖和自我更新,而对CD133表达水平没有显着影响,表明CD133 + 细胞比例与GIC1和GIC2的增殖与自我更新能力不一致是由PTEN缺乏引起的。为了进一步验证我们的结论,我们分析了一系列GIC,CD133 + 细胞的百分比不能反映PTEN缺陷型GIC中细胞增殖和自我更新特征的程度,这提示应用作为GIC制造商的CD133受PTEN损失的限制。此外,表达PTEN的GIC中PTEN的下调可能破坏CD133 + 细胞比例与增殖和自我更新能力之间的正相关性。我们的结果表明,PTEN的状态与神经胶质瘤起始细胞中的细胞增殖和自我更新与CD133表型无关,从而导致CD133作为PTEN缺陷型GICs的生物标记物的局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号